Clinical trials: Metastatic Renal Cancer
Renal Cell Cancer, Colorectal Cancer
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
The purpose of this study is to assess the influence of Sunitinib and Sorafenib on fatigue, quality of life and depression in patients with metastatic renal cell or colorectal cancer or GIST.
- Conditions
- Renal Cell Cancer, Colorectal Cancer, GIST
- Trial name
- NCT00979329
- Testing
- Questionnaires
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
AKI, CKD
Genetics in the Progression of Nephropathies
This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to: AKI CKD Hypertension ADPKD CKD-MBD Patients with decompensated heart failure undergoing either…
- Conditions
- AKI, CKD, Ckd-Mbd, CKD (Chronic Kidney Disease) Stage 5D
- Trial name
- NCT06416761
- Testing
- genetic polymorphisms
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Ospedale San Raffaele
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with bevacizumab and to see how well they work in treating patients with unresectable or metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324870
- Testing
- vorinostat, bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Radiation Therapy, Metastatic Renal Cancer
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually.
- Conditions
- Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
- Trial name
- COSTAR (NCT06583070)
- Testing
- Radiation therapy, Targeted and immunotherapy
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Metastatic Renal Cell Carcinoma
Urine Omics Predicting IO Therapy Responses in mRCC Patients
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
- Trial name
- NCT04712305
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital
Kidney Neoplasms
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.
- Trial name
- NCT04669366
- Testing
- sunitinib, axitinib
- Where
- Sweden
- Volunteers
- 1,205 people
- Sponsor
- Pfizer
Bladder Cancer, Urothelial Carcinoma
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma
- Trial name
- ATLAS (NCT03397394)
- Testing
- Rucaparib
- Where
- 64 sites in United States, France and 4 more
- Volunteers
- 97 people
- Sponsor
- pharmaand GmbH
Solid Tumor, Renal Cell Cancer Metastatic
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with…
- Conditions
- Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT04903873
- Testing
- EU101
- Where
- 6 sites in United States, South Korea
- Volunteers
- 110 people
- Sponsor
- Eutilex
Carcinoma, Renal Cell
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and…
- Trial name
- NCT00440973
- Testing
- Bevacizumab, Interleukin-2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Methodist Hospital Research Institute
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue…
- Conditions
- Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm
- Trial name
- NCT05756569
- Testing
- Biospecimen Collection, Computed Tomography, Enfortumab Vedotin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Carcinoma, Renal Cell
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
This is a uncontrolled, open-label, non-randomized Phase II study of oral BAY73-4506 to evaluate the response rate of BAY73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).
- Trial name
- NCT00664326
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 18 sites in United States, Finland and 4 more
- Volunteers
- 49 people
- Sponsor
- Bayer
Kidney Cancer
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003585
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of New Mexico
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related…
- Trial name
- OPTIMISE (NCT03140176)
- Testing
- Sunitinib
- Where
- 8 sites in Algeria, Egypt and 2 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Kidney Neoplasms
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
- Trial name
- NCT00920816
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 125 sites in United States, Bosnia and Herzegovina and 12 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage…
- Trial name
- NCT03393936
- Testing
- CCT301-38, CCT301-59
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.